

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



自然美

NATURAL BEAUTY

Natural Beauty Bio-Technology Limited

自然美生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00157)

**RESUMPTION GUIDANCE
AND
ADJOURNMENT OF THE ANNUAL GENERAL MEETING**

Reference is made to the announcements of Natural Beauty Bio-Technology Limited (the “**Company**”) dated 24 March 2020, 25 March 2020 and 29 April 2020 in relation to, among other things, the appointment of PricewaterhouseCoopers Management Consulting (Shanghai) Limited as the investigative agent to conduct an investigation on certain audit findings of the Company’s auditors (the “**Issues**”), Messrs. Deloitte Touche Tohmatsu (the “**Auditors**”) and the suspension in trading in the Company’s shares (the “**Shares**”).

RESUMPTION GUIDANCE

The board of directors of the Company (the “**Board**”) received a letter dated 20 May 2020 (the “**Letter**”) from The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”), in which the Stock Exchange sets out the following resumption guidance for the Company:

- (a) conduct an appropriate investigation into the Issues raised by the Auditors, announce the findings and take appropriate remedial actions;
- (b) publish all outstanding financial results and address any audit modifications; and
- (c) inform the market of all material information of the Company.

The Letter also states that the Company must remedy the issues causing its trading suspension and fully comply with the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”) to the Stock Exchange’s satisfaction before trading in its securities is allowed to resume and, for this purpose, the Company has the primary responsibility to devise its action plan for resumption. The Letter further sets out that the Stock Exchange may modify or supplement the resumption guidance if the Company’s situation changes. Under Rule 6.01A(1) of the Listing Rules, the Stock Exchange may cancel the Company’s listing if trading in the Company’s shares has remained suspended for 18 continuous months.

The 18-month period expires on 24 September 2021. If the Company fails to fulfil the resumption guidance and comply with the Listing Rules to the Stock Exchange’s satisfaction and resume trading in its shares by 24 September 2021, the Listing Division of the Stock Exchange will recommend the Listing Committee to proceed with the cancellation of the Company’s listing. Under Rule 6.10 of the Listing Rules, the Stock Exchange also has the right to impose a shorter specific remedial period where appropriate.

The Company will keep the holders of the securities of the Company and potential investors informed of the status and development of the Company as and when appropriate.

ADJOURNMENT OF THE ANNUAL GENERAL MEETING

As a result of the delay in publication of the audited financial results in respect of the financial year ended 31 December 2019 (“**2019 Annual Results**”) (which have been agreed with the Auditors) and delay in despatch of the annual report in respect of the financial year ended 31 December 2019 (“**2019 Annual Report**”), it is expected that the convening of the annual general meeting of the Company (the “**AGM**”) will be delayed until further notice. The Company will publish further announcement(s) to inform the shareholders of the Company of the date of publication of the audited 2019 Annual Results (which have been agreed with the Auditors), the date of despatch of the 2019 Annual Report and the date of the AGM by way of further announcement(s) as and when appropriate.

SUSPENSION OF TRADING

Trading in the Shares on the Stock Exchange has been suspended at the request of the Company since 9:00 a.m. on 25 March 2020 and will remain suspended until further notice. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Natural Beauty Bio-Technology Limited
LEI Chien
Chairperson

Hong Kong, 21 May 2020

As at the date of this announcement, the Board comprises Dr. Lei Chien and Mr. Pan Yi-Fan as executive directors; Ms. Lu Yu-Min, Ms. Lin Shu-Hua and Mr. Chen Shou-Huang as non-executive directors; and Mr. Chen Ruey-Long, Mr. Lu Chi-Chant and Mr. Yang Shih-Chien as independent non-executive directors.